Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats

被引:89
作者
Wu, Tingting
Dong, Zhe
Geng, Jing
Sun, Yingying
Liu, Guanghui
Kang, Weiqiang
Zhang, Yun
Ge, Zhiming [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Chinese Minist Hlth, Jinan 250012, Shandong, Peoples R China
关键词
Valsartan; DCM; Apoptosis; ER stress; CHOP; Puma; ENDOPLASMIC-RETICULUM STRESS; CELL-DEATH; HEART-FAILURE; DIASTOLIC DYSFUNCTION; CARDIOMYOPATHY; RECEPTOR; PUMA; CHOP; MANIFESTATION; ACTIVATION;
D O I
10.1016/j.ejps.2011.02.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recently studies indicated that valsartan could prevent the progression of heart failure caused by diabetic cardiomyopathy (DCM), while the mechanisms were still poorly understood. The present study was designed to investigate whether valsartan could reduce the endoplasmic reticulum (ER) stress and DCM-induced cardiac remodeling. Our data has shown that valsartan can ameliorate ER stress-induced cardiac remodeling and myocardial apoptosis in DCM rats. By using of immunofluorescence and RT-PCR, valsartan has been found to play a protective role via down-regulating the expression of transcriptional induction of C/EBP homologous protein (CHOP) and p53 upregulated modulator of apoptosis (Puma), two crucial factors known to be implicated in the ER stress-induced myocardial apoptosis. And the expression level of Puma was closely related to CHOP. Thus, our experiment strongly suggests that the administration of valsartan can ameliorate the ER stress through blocking the activation of CHOP/Puma signaling pathway, which provides a new insight into the potential molecular mechanism of cardiomyocyte apoptosis. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:496 / 502
页数:7
相关论文
共 41 条
[1]  
BHIMJI S, 1986, ACTA ANAT, V125, P195
[2]   Cellular response to endoplasmic reticulum stress: a matter of life or death [J].
Boyce, M ;
Yuan, J .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (03) :363-373
[3]   Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats [J].
Chan, P ;
Wong, KL ;
Liu, IM ;
Tzeng, TF ;
Yang, TL ;
Cheng, JT .
JOURNAL OF HYPERTENSION, 2003, 21 (04) :761-769
[4]   The mitochondrial death pathway and cardiac myocyte apoptosis [J].
Crow, MT ;
Mani, K ;
Nam, YJ ;
Kitsis, RN .
CIRCULATION RESEARCH, 2004, 95 (10) :957-970
[5]   Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus [J].
Diamant, M ;
Lamb, HJ ;
Groeneveld, Y ;
Endert, EL ;
Smit, JWA ;
Bax, JJ ;
Romijn, JA ;
de Roos, A ;
Radder, JK .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (02) :328-335
[6]   High glucose alters cardiomyocyte contacts and inhibits myofibrillar formation [J].
Dyntar, D ;
Sergeev, P ;
Klisic, J ;
Ambühl, P ;
Schaub, MC ;
Donath, MY .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (05) :1961-1967
[7]   Organelle-specific initiation of cell death pathways [J].
Ferri, KF ;
Kroemer, G .
NATURE CELL BIOLOGY, 2001, 3 (11) :E255-E263
[8]   Death begets failure in the heart [J].
Foo, RSY ;
Mani, K ;
Kitsis, RN .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (03) :565-571
[9]   Diabetic cardiomyopathy: mechanisms, diagnosis and treatment [J].
Hayat, SA ;
Patel, B ;
Khattar, RS ;
Malik, RA .
CLINICAL SCIENCE, 2004, 107 (06) :539-557
[10]   A FUNCTIONAL AND ULTRASTRUCTURAL ANALYSIS OF EXPERIMENTAL DIABETIC RAT MYOCARDIUM - MANIFESTATION OF A CARDIOMYOPATHY [J].
JACKSON, CV ;
MCGRATH, GM ;
TAHILIANI, AG ;
VADLAMUDI, RVSV ;
MCNEILL, JH .
DIABETES, 1985, 34 (09) :876-884